Estrogen receptor beta in prostate cancer: Friend or foe?

Endocrine-Related Cancer

Volumn 21, Issue 4, 2014, Pages

  Nelson, Adam W ^a,b   Tilley, Wayne D ^a,c   Neal, David E ^a,b   Carroll, Jason S ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Androgen; Cancer; Estrogen; Estrogen receptor beta; Prostate

Indexed keywords

ANDROGEN; AROMATASE; ESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGEN RECEPTOR BETA 1; ESTROGEN RECEPTOR BETA 2; ESTROGEN RECEPTOR BETA 3; ESTROGEN RECEPTOR BETA 4; ESTROGEN RECEPTOR BETA 5; FLAVONOID; FULVESTRANT; GENISTEIN; HORMONE RECEPTOR; ISOFLAVONE; LIGNAN DERIVATIVE; PHYTOESTROGEN; PLACEBO; RALOXIFENE; TAMOXIFEN; TETRACYCLINE; TOREMIFENE; UNCLASSIFIED DRUG;

ANDROGEN BLOOD LEVEL; APOPTOSIS; CANCER CELL; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESEARCH; CARCINOGENESIS; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; ESTROGEN BLOOD LEVEL; EVIDENCE BASED MEDICINE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MEDIATOR; NONHUMAN; PROSTATE; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN FUNCTION; REVIEW; ANIMAL; DISEASE COURSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROSTATIC NEOPLASMS;

ANIMALS; DISEASE PROGRESSION; ESTROGEN RECEPTOR BETA; ESTROGENS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PROSTATE; PROSTATIC NEOPLASMS;

EID: 84905993593     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-13-0508     Document Type: Review

References (157)

1. Abd Elmageed ZY, Moroz K, Srivastav SK, Fang Z, Crawford BE, Moparty K, Thomas R & Abdel-Mageed AB 2013 High circulating estrogens and selective expression of ERb in prostate tumors: implications for racial disparity of prostate cancer. Carcinogenesis 34 2017-23. (doi:10.1093/carcin/bgt156)
2. Andersen RJ,Mawji NR,Wang J,Wang G, Haile S, Myung JK, Watt K, TamT, Yang YC, Banuelos CA et al. 2010 Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 17 535-546. (doi:10.1016/j.ccr.2010.04.027)
3. Andres S, Abraham K, Appel KE & Lampen A 2011 Risks and benefits of dietary isoflavones for cancer. Critical Reviews in Toxicology 41 463-506. (doi:10.3109/10408444.2010.541900)
4. Arai Y, Chen CY & Nishizuka Y 1978 Cancer development in male reproductive tract in rats given diethylstilbestrol at neonatal age. Gann 69 861-862. (Pubitemid 9081600)
5. Asgari M & Morakabati A 2011 Estrogen receptor β expression in prostate adenocarcinoma. Diagnostic Pathology 6 61. (doi:10.1186/1746-1596-6-61)
6. Attard G, Richards J & de Bono JS 2011 New strategies inmetastatic prostate cancer: targeting the androgen receptor signaling pathway. Clinical Cancer Research 17 1649-1657. (doi:10.1158/1078-0432.CCR-10-0567)
7. Attia DM & Ederveen AG 2012 Opposing roles of ERα and ERβ in the genesis and progression of adenocarcinoma in the rat ventral prostate. Prostate 72 1013-1022. (doi:10.1002/pros.21507)
8. Barth JH, Field HP, Yasmin E & Balen AH 2010 Defining hyperandrogenism in polycystic ovary syndrome: measurement of testosterone and androstenedione by liquid chromatography-tandem mass spectrometry and analysis by receiver operator characteristic plots. European Journal of Endocrinology 162 611-615. (doi:10.1530/EJE-09-0741)
9. Bergan RC, Reed E, Myers CE, Headlee D, Brawley O, Cho HK, Figg WD, Tompkins A, Linehan WM, Kohler D et al. 1999 A phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer. Clinical Cancer Research 5 2366-2373. (Pubitemid 29437315)
10. Bianco JJ, Handelsman DJ, Pedersen JS & Risbridger GP 2002 Direct response of the murine prostate gland and seminal vesicles to estradiol. Endocrinology 143 4922-4933. (doi:10.1210/en.2002-220493)
11. Bianco JJ, McPherson SJ, Wang H, Prins GS & Risbridger GP 2006 Transient neonatal estrogen exposure to estrogen-deficient mice (aromatase knockout) reduces prostate weight and induces inflammation in late life. American Journal of Pathology 168 1869-1878. (doi:10.2353/ajpath.2006.050623)
12. Bonkhoff H & Berges R 2009 The evolving role of oestrogens and their receptors in the development and progression of prostate cancer. European Urology 55 533-542. (doi:10.1016/j.eururo.2008.10.035)
13. Bosland MC 2013 A perspective on the role of estrogen in hormone-induced prostate carcinogenesis. Cancer Letters 334 28-33. (doi:10.1016/j.canlet.2012. 08.027)
14. Bottner M, Thelen P & Jarry H 2014 Estrogen receptor β: tissue distribution and the still largely enigmatic physiological function. Journal of Steroid Biochemistry and Molecular Biology 139 245-51. (doi:10.1016/j.jsbmb. 2013.03.003)
15. Bouchal J, Santer FR, Hoschele PP, Tomastikova E, Neuwirt H & Culig Z 2011 Transcriptional coactivators p300 and CBP stimulate estrogen receptor-β signaling and regulate cellular events in prostate cancer. Prostate 71 431-437. (doi:10.1002/pros.21257)
16. Bubendorf L, Kononen J, Koivisto P, Schraml P,Moch H, Gasser TC, Willi N, Mihatsch MJ, Sauter G & Kallioniemi OP 1999 Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Research 59 803-806. (Pubitemid 29086730)
17. Cai C & Balk SP 2011 Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. Endocrine-Related Cancer 18 R175-R182. (doi:10.1530/ERC-10-0339)
18. Carroll JS, Liu XS, Brodsky AS, Li W, Meyer CA, Szary AJ, Eeckhoute J, Shao W, Hestermann EV, Geistlinger TR et al. 2005 Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 122 33-43. (doi:10.1016/j.cell.2005.05.008)
19. Carroll JS,Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J, Brodsky AS, Keeton EK, Fertuck KC, Hall GF et al. 2006 Genome-wide analysis of estrogen receptor binding sites. Nature Genetics 38 1289-1297. (doi:10.1038/ng1901)
20. Carruba G 2007 Estrogen and prostate cancer: an eclipsed truth in an androgen-dominated scenario. Journal of Cellular Biochemistry 102 899-911. (doi:10.1002/jcb.21529)
21. Celhay O, Yacoub M, Irani J, Dore B, Cussenot O & Fromont G 2010 Expression of estrogen related proteins in hormone refractory prostate cancer: association with tumor progression. Journal of Urology 184 2172-2178. (doi:10.1016/j.juro.2010.06.089)
22. Centenera MM, Gillis JL, Hanson AR, Jindal S, Taylor RA, Risbridger GP, Sutherland PD, Scher HI, Raj GV, Knudsen KE et al. 2012 Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors. Clinical Cancer Research 18 3562-3570. (doi:10.1158/1078-0432.CCR-12-0782)
23. Chadha MK, Ashraf U, Lawrence D, Tian L, Levine E, Silliman C, Escott P, Payne V & Trump DL 2008 Phase II study of fulvestrant (Faslodex) in castration resistant prostate cancer. Prostate 68 1461-1466. (doi:10.1002/pros.20813)
24. Chang WY & Prins GS 1999 Estrogen receptor-β: implications for the prostate gland. Prostate 40 115-124. (doi:10.1002/(SICI)1097-0045(19990701) 40:2〈11)
25. Chantzi NI, Tiniakos DG, Palaiologou M, Goutas N, Filippidis T, Vassilaros SD, Dhimolea E, Mitsiou DJ & Alexis MN 2013 Estrogen receptor β2 is associated with poor prognosis in estrogen receptor α-negative breastcarcinoma. Journal of Cancer Research and Clinical Oncology 139 1489-1498. (doi:10.1007/s00432-013-1467-4)
26. Chen M, Ni J, Chang HC, Lin CY, Muyan M & Yeh S 2009 CCDC62/ERAP75 functions as a coactivator to enhance estrogen receptor β- mediatedtransactivation and target gene expression in prostate cancer cells. Carcinogenesis 30 841-850. (doi:10.1093/carcin/bgn288)
27. Chmelar R, Buchanan G, Need EF, Tilley W & Greenberg NM 2007 Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. International Journal of Cancer 120 719-733. (doi:10.1002/ijc.22365)
28. Cotrim CZ, Fabris V, Doria ML, Lindberg K, Gustafsson JA, Amado F, Lanari C & Helguero LA 2013 Estrogen receptor β growth-inhibitory effects are repressed through activation of MAPK and PI3K signalling inmammary epithelial and breast cancer cells. Oncogene 32 2390-2402. (doi:10.1038/onc.2012.261)
29. Cussenot O, Azzouzi AR, Nicolaiew N, Fromont G, Mangin P, Cormier L, Fournier G, Valeri A, Larre S, Thibault F et al. 2007 Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: the hidden face of estrogens. Journal of Clinical Oncology 25 3596-3602. (doi:10.1200/JCO.2007.11.0908)
30. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL & Tindall DJ 2008 Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Research 68 5469-5477. (doi:10.1158/0008-5472.CAN-08-0594)
31. Dey P, Jonsson P, Hartman J,Williams C, Strom A & Gustafsson JA 2012 Estrogen receptors b1 and b2 have opposing roles in regulating proliferation and bone metastasis genes in the prostate cancer cell line PC3. Molecular Endocrinology 26 1991-2003. (doi:10.1210/me.2012.1227)
32. Dey P, Barros RP, Warner M, Strom A & Gustafsson JA 2013a Insight into the mechanisms of action of estrogen receptor b. Journal of Molecular Endocrinology 51 T61-T74. (doi:10.1530/JME-13-0150)
33. Dey P, Strom A & Gustafsson JA 2013b Estrogen receptor β upregulates FOXO3a and causes induction of apoptosis through PUMA in prostate cancer. Oncogene. (doi:10.1038/onc.2013.384)
34. Ellem SJ & Risbridger GP 2007 Treating prostate cancer: a rationale for targeting local oestrogens. Nature Reviews. Cancer 7 621-627. (doi:10.1038/nrc2174)
35. Ellem SJ, Schmitt JF, Pedersen JS, Frydenberg M & Risbridger GP 2004 Local aromatase expression in human prostate is altered in malignancy. Journal of Clinical Endocrinology and Metabolism 89 2434-2441. (doi:10.1210/jc.2003- 030933)
36. Enmark E, Pelto-Huikko M, Grandien K, Lagercrantz S, Lagercrantz J, Fried G, Nordenskjold M & Gustafsson JA 1997 Human estrogen receptor β-gene structure, chromosomal localization, and expression pattern.Journal of Clinical Endocrinology and Metabolism 82 4258-4265. (Pubitemid 27525550)
37. Foryst-Ludwig A, Clemenz M, Hohmann S, Hartge M, Sprang C, Frost N, Krikov M, Bhanot S, Barros R, Morani A et al. 2008 Metabolic actions of estrogen receptor b (ERb) are mediated by a negative cross-talk with PPARg. PLoS Genetics 4 e1000108. (doi:10.1371/journal.pgen.1000108)
38. Ganmaa D, Li XM, Qin LQ, Wang PY, Takeda M & Sato A 2003 The experience of Japan as a clue to the etiology of testicular and prostatic cancers. Medical Hypotheses 60 724-730. (doi:10.1016/S0306-9877(03)00047-1)
39. Ghosh D, Griswold J, Erman M & Pangborn W 2009 Structural basis for androgen specificity and oestrogen synthesis in human aromatase. Nature 457 219-223. (doi:10.1038/nature07614)
40. Grubisha MJ & Defranco DB 2013 Local endocrine, paracrine and redox signaling networks impact estrogen and androgen crosstalk in the prostate cancer microenvironment. Steroids 78 538-541. (doi:10.1016/j.steroids.2013.01.005)
41. Grubisha MJ, Cifuentes ME, Hammes SR & Defranco DB 2012 A local paracrine and endocrine network involving TGFb, Cox-2, ROS, and estrogen receptor b influences reactive stromal cell regulation of prostate cancer cell motility. Molecular Endocrinology 26 940-954. (doi:10.1210/me.2011-1371)
42. Guarino M, Rubino B & Ballabio G 2007 The role of epithelial- mesenchymal transition in cancer pathology. Pathology 39 305-318. (doi:10.1080/00313020701329914)
43. Haldosen LA, Zhao C & Dahlman-Wright K 2014 Estrogen receptor βin breast cancer. Molecular and Cellular Endocrinology 382 665-72. (doi:10.1016/j.mce.2013.08.005)
44. Hanahan D & Weinberg RA 2011 Hallmarks of cancer: the next generation. Cell 144 646-674. (doi:10.1016/j.cell.2011.02.013)
45. Hanstein B, Liu H, Yancisin MC & Brown M 1999 Functional analysis of a novel estrogen receptor-β isoform. Molecular Endocrinology 13 129-137. (Pubitemid 29022285)
46. Harris HA 2007 Estrogen receptor-β: recent lessons from in vivo studies. Molecular Endocrinology 21 1-13. (doi:10.1210/me.2005-0459)
47. Harris HA, Albert LM, Leathurby Y, Malamas MS, Mewshaw RE, Miller CP, Kharode YP, Marzolf J, KommBS, Winneker RC et al. 2003 Evaluation of an estrogen receptor-β agonist in animal models of human disease. Endocrinology 144 4241-4249. (doi:10.1210/en.2003-0550)
48. Hartman J, Strom A & Gustafsson JA 2012 Current concepts and significance of estrogen receptor β in prostate cancer. Steroids 77 1262-1266. (doi:10.1016/j.steroids.2012.07.002)
49. Hedelin M, Balter KA, Chang ET, Bellocco R, Klint A, Johansson JE, Wiklund F, Thellenberg-Karlsson C, Adami HO & Gronberg H 2006 Dietary intake of phytoestrogens, estrogen receptor-b polymorphisms and the risk of prostate cancer. Prostate 66 1512-1520. (doi:10.1002/pros.20487)
50. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T et al. 2011 EAU guidelines on prostate cancer, Part 1: screening, diagnosis, and treatment of clinically localised disease. European Urology 59 61-71. (doi:10.1016/j.eururo.2010.10.039)
51. Hickey TE & Norman RJ 2010 Biomarkers: polycystic ovary syndrome: steroid assessment for diagnosis. Nature Reviews. Endocrinology 6 305-307. (doi:10.1038/nrendo.2010.68)
52. Holbeck S, Chang J, Best AM, Bookout AL, Mangelsdorf DJ & Martinez ED 2010 Expression profiling of nuclear receptors in the NCI60 cancer cell panel reveals receptor-drug and receptor-gene interactions. Molecular Endocrinology 24 1287-1296. (doi:10.1210/me.2010-0040)
53. Hollier BG, Evans K & Mani SA 2009 The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies. Journal of Mammary Gland Biology & Neoplasia 14 29-43. (doi:10.1007/s10911-009-9110- 3)
54. Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, Ryan C, Smith S, Scher H, Scardino P et al. 2004 Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. American Journal of Pathology 164 217-227. (doi:10.1016/S0002-9440(10)63112-4)
55. Hori S, Butler E & McLoughlin J 2011 Prostate cancer and diet: food for thought? BJU International 107 1348-1359. (doi:10.1111/j.1464-410X.2010. 09897.x)
56. Horvath LG, HenshallSM, Lee CS,HeadDR,QuinnDI,Makela S,DelpradoW, Golovsky D, Brenner PC, O'Neill G et al. 2001 Frequent loss of estrogen receptor-β expression in prostate cancer. Cancer Research 61 5331-5335. (Pubitemid 32694904)
57. Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, Edwards J, Isaacs WB, Nelson PS, Bluemn E et al. 2012 Distinct transcriptional programsmediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Research 72 3457-3462. (doi:10.1158/0008-5472.CAN-11-3892)
58. Huggins C 1943 Endocrine control of prostatic cancer. Science 97 541-544. (doi:10.1126/science.97.2529.541)
59. Huggins C & Hodges CV 1972 Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA: A Cancer Journal for Clinicians 22 232-240. (doi:10.3322/canjclin.22.4.232)
60. Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D & Carroll JS 2011 FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nature Genetics 43 27-33. (doi:10.1038/ng.730)
61. Hussain S, Lawrence MG, Taylor RA, Lo CY, Frydenberg M, Ellem SJ, Furic L & Risbridger GP 2012 Estrogen receptor b activation impairs prostatic regeneration by inducing apoptosis in murine and human stem/progenitor enriched cell populations. PLoS ONE 7 e40732. (doi:10.1371/journal.pone.0040732)
62. Ishizaki F, Nishiyama T, Kawasaki T,Miyashiro Y,Hara N, Takizawa I, NaitoM & Takahashi K 2013 Androgen deprivation promotes intratumoral synthesis of dihydrotestosterone from androgen metabolites in prostate cancer. Scientific Reports 3 1528. (doi:10.1038/srep01528)
63. Jiang Y, Gong P, Madak-Erdogan Z, Martin T, Jeyakumar M, Carlson K, Khan I, Smillie TJ, Chittiboyina AG, Rotte SC et al. 2013 Mechanisms enforcing the estrogen receptor b selectivity of botanical estrogens. FASEB Journal 27 4406-4418. (doi:10.1096/fj.13-234617)
64. Johnson BE, Whang-Peng J, Naylor SL, Zbar B, Brauch H, Lee E, Simmons A, Russell E, Nam MH & Gazdar AF 1989 Retention of chromosome 3 in extrapulmonary small cell cancer shown by molecular and cytogenetic studies. Journal of the National Cancer Institute 81 1223-1228. (doi:10.1093/jnci/81.16. 1223)
65. de Jong FH, Oishi K, Hayes RB, Bogdanowicz JF, Raatgever JW, van der Maas PJ, Yoshida O & Schroeder FH 1991 Peripheral hormone levels in controls and patients with prostatic cancer or benign prostatic hyperplasia: results from the Dutch-Japanese case-control study. Cancer Research 51 3445-3450.
66. Kangas L 1990 Review of the pharmacological properties of toremifene. Journal of Steroid Biochemistry 36 191-195. (doi:10.1016/0022-4731(90)90003-B)
67. Kim IY, Kim BC, Seong DH, Lee DK, Seo JM, Hong YJ, Kim HT, Morton RA &Kim SJ 2002a Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines. Cancer Research 62 5365-5369. (Pubitemid 35024614)
68. Kim IY, Seong DH, Kim BC, Lee DK, Remaley AT, Leach F, Morton RA & Kim SJ 2002b Raloxifene, a selective estrogen receptor modulator, induces apoptosis in androgen-responsive human prostate cancer cell line LNCaP through an androgen-independent pathway. Cancer Research 62 3649-3653. (Pubitemid 34728841)
69. Knudsen KE & Penning TM 2010 Partners incrime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends in Endocrinology and Metabolism 21 315-324. (doi:10.1016/j.tem.2010.01.002)
70. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S & Gustafsson JA 1996 Cloning of a novel receptor expressed in rat prostate and ovary. PNAS 93 5925-5930. (doi:10.1073/pnas.93.12.5925)
71. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van der Burg B & Gustafsson JA 1998 Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology 139 4252-4263. (Pubitemid 28513713)
72. Lai SL, Brauch H, Knutsen T, Johnson BE, Nau MM, Mitsudomi T, Tsai CM, Whang-Peng J, Zbar B, Kaye FJ et al. 1995 Molecular genetic characterization of neuroendocrine lung cancer cell lines. Anticancer Research 15 225-232.
73. Lamb AD, Massie CE & Neal DE 2013 The transcriptional program of the androgen receptor (AR) in prostate cancer. BJU International. (doi:10.1111/bju.12415)
74. Langley RE, Cafferty FH, Alhasso AA, Rosen SD, Sundaram SK, Freeman SC, Pollock P, Jinks RC, Godsland IF, Kockelbergh R et al. 2013 Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasinghormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09). Lancet Oncology 14 306-316. (doi:10.1016/ S1470-2045(13)70025-1)
75. Lau KM, LaSpina M, Long J & Ho SM 2000 Expression of estrogen receptor (ER)-a and ER-b in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. Cancer Research 60 3175-3182. (Pubitemid 30407914)
76. Lawrence MG, Taylor RA, Toivanen R, Pedersen J, Norden S, Pook DW, Frydenberg M, Papargiris MM, Niranjan B, Richards MG et al. 2013 A preclinical xenograft model of prostate cancer using human tumors. Nature Protocols 8 836-848. (doi:10.1038/nprot.2013.043)
77. Le TP, Sun M, Luo X, Kraus WL & Greene GL 2013 Mapping ERβ genomic binding sites reveals unique genomic features and identifies EBF1 as an ERβ interactor. PLoS ONE 8 e71355. (doi:10.1371/journal.pone.0071355)
78. Leav I, Lau KM, Adams JY, McNeal JE, Taplin ME, Wang J, Singh H & Ho SM 2001 Comparative studies of the estrogen receptors β and α and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. American Journal of Pathology 159 79-92. (doi:10.1016/S0002-9440(10)61676-8)
79. Leung YK, Gao Y, Lau KM, Zhang X & Ho SM 2006a ICI 182,780-regulated gene expression in DU145 prostate cancer cells is mediated by estrogen receptor-β/NFκB crosstalk. Neoplasia 8 242-249. (doi:10.1593/neo. 05853)
80. Leung YK, Mak P, Hassan S & Ho SM 2006b Estrogen receptor (ER)-βisoforms: a key to understanding ER-β signaling. PNAS 103 13162-13167. (doi:10.1073/pnas.0605676103)
81. Leung YK, Lam HM, Wu S, Song D, Levin L, Cheng L, Wu CL & Ho SM2010 Estrogen receptor β2 and β5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion. Endocrine-Related Cancer 17 675-689. (doi:10.1677/ERC-09-0294)
82. Li YM, Xu SC, Li J, Han KQ, Pi HF, Zheng L, Zuo GH, Huang XB, Li HY, Zhao HZ et al. 2013 Epithelial-mesenchymal transition markers expressed in circulating tumor cells in hepatocellular carcinoma patients with different stages of disease. Cell Death & Disease 4 e831. (doi:10.1038/cddis.2013.347)
83. Lumachi F, Luisetto G, Basso SM, Basso U, Brunello A & Camozzi V 2011 Endocrine therapy of breast cancer. Current Medicinal Chemistry 18 513-522. (doi:10.2174/092986711794480177)
84. Madak-Erdogan Z, Charn TH, Jiang Y, Liu ET, Katzenellenbogen JA & Katzenellenbogen BS 2013 Integrative genomics of gene and metabolic regulation by estrogen receptors α and β, and their coregulators. Molecular Systems Biology 9 676. (doi:10.1038/msb.2013.28)
85. Mak P, Chang C, Pursell B & Mercurio AM 2013 Estrogen receptor β sustains epithelial differentiation by regulating prolyl hydroxylase 2 transcription. PNAS 110 4708-4713. (doi:10.1073/pnas.1221654110)
86. Massie CE, Lynch A, Ramos-Montoya A, Boren J, Stark R, Fazli L, Warren A, Scott H, Madhu B, Sharma N et al. 2011 The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO Journal 30 2719-2733. (doi:10.1038/emboj.2011.158)
87. McPherson SJ, Ellem SJ & Risbridger GP 2008 Estrogen-regulated development and differentiation of the prostate. Differentiation 76 660-670. (doi:10.1111/j.1432-0436.2008.00291.x)
88. McPherson SJ, Hussain S, Balanathan P, Hedwards SL, Niranjan B, Grant M, Chandrasiri UP, Toivanen R, Wang Y, Taylor RA et al. 2010 Estrogen receptor-β activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFα mediated. PNAS 107 3123-3128. (doi:10.1073/pnas.0905524107)
89. Menasce LP, White GR, Harrison CJ & Boyle JM 1993 Localization of the estrogen receptor locus (ESR) to chromosome 6q25.1 by FISH and a simple post-FISH banding technique. Genomics 17 263-265. (doi:10.1006/geno.1993.1320)
90. Merrimen JL, Jones G, Walker D, Leung CS, Kapusta LR & Srigley JR 2009 Multifocal high grade prostatic intraepithelial neoplasia is a significant risk factor for prostatic adenocarcinoma. Journal of Urology 182 485-490 discussion 490. (doi:10.1016/j.juro.2009.04.016)
91. Mertz KD, Setlur SR, Dhanasekaran SM, Demichelis F, Perner S, Tomlins S, Tchinda J, Laxman B, Vessella RL, Beroukhim R et al. 2007 Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. Neoplasia 9 200-206. (doi:10.1593/neo.07103)
92. Messina M 2010 Insights gained from 20 years of soy research. Journal of Nutrition 140 2289S-2295S. (doi:10.3945/jn.110.124107)
93. Moore JT, McKee DD, Slentz-Kesler K, Moore LB, Jones SA, Horne EL, Su JL, Kliewer SA, Lehmann JM & Willson TM 1998 Cloning and characterization of human estrogen receptor β isoforms. Biochemical and Biophysical Research Communications 247 75-78. (doi:10.1006/bbrc.1998.8738)
94. Morales A & Pujari B 1975 The choice of estrogen preparations in the treatment of prostatic cancer. Canadian Medical Association Journal 113 865-867.
95. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F et al. 2011 EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. European Urology 59 572-583. (doi:10.1016/j.eururo.2011.01.025)
96. Muthusamy S, Andersson S, Kim HJ, Butler R, Waage L, Bergerheim U & Gustafsson JA 2011 Estrogen receptor b and 17β-hydroxysteroid dehydrogenase type 6, a growth regulatory pathway that is lost inprostate cancer. PNAS 108 20090-20094. (doi:10.1073/pnas.1117772108)
97. Nakajima Y, Akaogi K, Suzuki T, Osakabe A, Yamaguchi C, Sunahara N, Ishida J, Kako K, Ogawa S, Fujimura T et al. 2011 Estrogen regulates tumor growth through a nonclassical pathway that includes the transcription factors ERb and KLF5. Science Signaling 4 ra22. (doi:10.1126/scisignal.2001551)
98. Nakamura H, Wang Y, Xue H, Romanish MT, Mager DL, Helgason CD & Wang Y 2013 Genistein versus ICI 182, 780: an ally or enemy in metastatic progression of prostate cancer. Prostate 73 1747-1760. (doi:10.1002/pros.22712)
99. Nelles JL, Hu WY & Prins GS 2011 Estrogen action and prostate cancer. Expert Review of Endocrinology & Metabolism 6 437-451. (doi:10.1586/eem.11. 20)
100. Nelson WG, De Marzo AM & Isaacs WB 2003 Prostate cancer. New England Journal of Medicine 349 366-381. (doi:10.1056/NEJMra021562)
101. Oliveira AG, Coelho PH, Guedes FD, Mahecha GA, Hess RA & Oliveira CA 2007 5α-Androstane-3β,17β-diol (3β-diol), an estrogenic metabolite of5α-dihydrotestosterone, is a potent modulator of estrogen receptor ERßexpression in the ventral prostrate of adult rats. Steroids 72 914-922. (doi:10.1016/j.steroids.2007.08.001)
102. Pinzone JJ, Stevenson H, Strobl JS & Berg PE 2004 Molecular and cellular determinants of estrogen receptor α expression. Molecular and Cellular Biology 24 4605-4612. (doi:10.1128/MCB.24.11.4605-4612.2004)
103. Price D, Stein B, Sieber P, Tutrone R, Bailen J, Goluboff E, Burzon D, Bostwick D & Steiner M 2006 Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial. Journal of Urology 176 965-970 discussion 970-961. (doi:10.1016/j.juro.2006.04.011)
104. Prins GS & Birch L 1997 Neonatal estrogen exposure up-regulates estrogen receptor expression in the developing and adult rat prostate lobes. Endocrinology 138 1801-1809. (Pubitemid 27180792)
105. Prins GS & Korach KS 2008 The role of estrogens and estrogen receptors in normal prostate growth and disease. Steroids 73 233-244. (doi:10.1016/j.steroids.2007.10.013)
106. Prins GS, Huang L, Birch L & Pu Y 2006 The role of estrogens in normal and abnormal development of the prostate gland. Annals of the New York Academy of Sciences 1089 1-13. (doi:10.1196/annals.1386.009)
107. Prins GS, Birch L, Tang WY & Ho SM 2007 Developmental estrogen exposures predispose to prostate carcinogenesis with aging. Reproductive Toxicology 23 374-382. (doi:10.1016/j.reprotox.2006.10.001)
108. Qu X, Randhawa G, Friedman C, Kurland BF, Glaskova L, Coleman I, Mostaghel E, Higano CS, Porter C, Vessella R et al. 2013 A three-marker FISH panel detects more genetic aberrations of, and in castrationresistant or metastatic prostate cancers than in primary prostate tumors. PLoS ONE 8 e74671. (doi:10.1371/journal.pone.0074671)
109. Razzak M 2013 Prostate cancer: not guilty-TMPRSS2-ERG does not sensitize cells to radiation. Nature Reviews. Urology 10 556. (doi:10.1038/nrurol.2013. 188)
110. Reiter E, Gerster P & Jungbauer A 2011 Red clover and soy isoflavones - an in vitro safety assessment. Gynecological Endocrinology 27 1037-1042. (doi:10.3109/09513590.2011.588743)
111. Ricke WA, McPherson SJ, Bianco JJ, Cunha GR, Wang Y & Risbridger GP 2008 Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor a signaling. FASEB Journal 22 1512-1520. (doi:10.1096/fj.07-9526com)
112. Risbridger GP, Ellem SJ & McPherson SJ 2007 Estrogen action on the prostate gland: a critical mix of endocrine and paracrine signaling. Journal of Molecular Endocrinology 39 183-188. (doi:10.1677/JME-07-0053)
113. Robinson JL, Macarthur S, Ross-Innes CS, Tilley WD, Neal DE, Mills IG & Carroll JS 2011 Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO Journal 30 3019-3027. (doi:10.1038/emboj.2011.216)
114. Rody A, Holtrich U, Solbach C, Kourtis K, von Minckwitz G, Engels K, Kissler S, Gatje R, Karn T & Kaufmann M 2005 Methylation of estrogen receptor β promoter correlates with loss of ER-β expression in mammary carcinoma and is an early indication marker in premalignant lesions. Endocrine-Related Cancer 12 903-916. (doi:10.1677/erc.1.01088)
115. Rohlff C, Blagosklonny MV, Kyle E, Kesari A, Kim IY, Zelner DJ, Hakim F, Trepel J & Bergan RC 1998 Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21(waf1/cip1). Prostate 37 51-59. (doi:10.1002/(SICI)1097-0045(19980915)37: 1〈51)
116. Rohrmann S, Nelson WG, Rifai N, Brown TR, Dobs A, Kanarek N, Yager JD & Platz EA 2007 Serum estrogen, but not testosterone, levels differ between black and white men in a nationally representative sample of Americans. Journal of Clinical Endocrinology and Metabolism 92 2519-2525. (doi:10.1210/jc.2007- 0028)
117. Ross RK, Bernstein L, Lobo RA, Shimizu H, Stanczyk FZ, Pike MC &Henderson BE 1992 5-α-reductase activity and risk of prostate canceramong Japanese and US white and black males. Lancet 339 887-889. (doi:10.1016/0140-6736(92)90927-U)
118. Rossi V, Bellastella G, De Rosa C, Abbondanza C, Visconti D, Maione L, Chieffi P, Della Ragione F, Prezioso D, De Bellis A et al. 2011 Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptor α and β. Journal of Cellular Physiology 226 1334-1339. (doi:10.1002/jcp.22461)
119. Roy S, Chakravarty D, Cortez V, De Mukhopadhyay K, Bandyopadhyay A, Ahn JM, Raj GV, Tekmal RR, Sun L & Vadlamudi RK 2012 Significance of PELP1 in ER-negative breast cancer metastasis. Molecular Cancer Research 10 25-33. (doi:10.1158/1541-7786.MCR-11-0456)
120. Ruizeveld de Winter JA, Trapman J, Vermey M, Mulder E, Zegers ND & van der Kwast TH 1991 Androgen receptor expression in human tissues: an immunohistochemical study. Journal of Histochemistry and Cytochemistry 39 927-936. (doi:10.1177/39.7.1865110)
121. Sahu B, Laakso M, Ovaska K, Mirtti T, Lundin J, Rannikko A, Sankila A, Turunen JP, Lundin M, Konsti J et al. 2011 Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. EMBO Journal 30 3962-3976. (doi:10.1038/emboj.2011.328)
122. Santen RJ, Santner SJ, Pauley RJ, Tait L, Kaseta J, Demers LM, Hamilton C, Yue W & Wang JP 1997 Estrogen production via the aromatase enzyme in breast carcinoma: which cell type is responsible? Journal of Steroid Biochemistry and Molecular Biology 61 267-271. (doi:10.1016/ S0960-0760(97)80022-2)
123. Scher HI, Buchanan G, Gerald W, Butler LM & Tilley WD 2004 Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocrine-Related Cancer 11 459-476. (doi:10.1677/ erc.1.00525)
124. Setlur SR, Mertz KD, Hoshida Y, Demichelis F, Lupien M, Perner S, Sboner A, Pawitan Y, Andren O, Johnson LA et al. 2008 Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. Journal of the National Cancer Institute 100 815-825. (doi:10.1093/jnci/djn150)
125. Shaaban AM, O'Neill PA, Davies MP, Sibson R,West CR, Smith PH & Foster CS 2003 Declining estrogen receptor-β expression defines malignant progression of human breast neoplasia. American Journal of Surgical Pathology 27 1502-1512. (doi:10.1097/00000478-200312000-00002)
126. Sharma NL, Massie CE, Ramos-Montoya A, Zecchini V, Scott HE, Lamb AD, MacArthur S, Stark R, Warren AY, Mills IG et al. 2013 The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. Cancer Cell 23 35-47. (doi:10.1016/j.ccr.2012.11.010)
127. Shen JC, Klein RD, Wei Q, Guan Y, Contois JH, Wang TT, Chang S & Hursting SD 2000 Low-dose genistein induces cyclin-dependent kinase inhibitors and G(1) cell-cycle arrest in human prostate cancer cells. Molecular Carcinogenesis 29 92-102. (doi:10.1002/1098- 2744(200010)29:2〈92::AID- MC6〉3.0.CO;2-Q)
128. Shozu M, Zhao Y & Simpson ER 2000 TGF-β1 stimulates expression of the aromatase (CYP19) gene in human osteoblast-like cells and THP-1 cells. Molecular and Cellular Endocrinology 160 123-133. (doi:10.1016/S0303-7207(99) 00233-6)
129. Sissung TM, Danesi R, Kirkland CT, BaumCE, Ockers SB, Stein EV, VenzonD, Price DK & Figg WD 2011 Estrogen receptor α and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapy. Journal of Clinical Endocrinology and Metabolism 96 E368-E372. (doi:10.1210/jc.2010-2070)
130. Skliris GP, Parkes AT, Limer JL, Burdall SE, Carder PJ & Speirs V 2002 Evaluation of seven oestrogen receptor β antibodies for immunohistochemistry, western blotting, and flow cytometry in human breast tissue. Journal of Pathology 197 155-162. (doi:10.1002/path.1077)
131. Stener-Victorin E, Holm G, Labrie F, Nilsson L, Janson PO & Ohlsson C 2010 Are there any sensitive and specific sex steroid markers for polycystic ovary syndrome? Journal of Clinical Endocrinology and Metabolism 95 810-819. (doi:10.1210/jc.2009-1908)
132. Stettner M, Kaulfuss S, Burfeind P, Schweyer S, Strauss A, Ringert RH & Thelen P 2007 The relevance of estrogen receptor-β expression to the antiproliferative effects observed with histone deacetylase inhibitors and phytoestrogens in prostate cancer treatment. Molecular Cancer Therapeutics 6 2626-2633. (doi:10.1158/1535-7163.MCT-07-0197)
133. Subbaramaiah K, Howe LR, Bhardwaj P, Du B, Gravaghi C, Yantiss RK, Zhou XK, Blaho VA, Hla T, Yang P et al. 2011 Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prevention Research 4 329-346. (doi:10.1158/ 1940-6207.CAPR-10-0381)
134. Suzuki F, Akahira J, Miura I, Suzuki T, Ito K, Hayashi S, Sasano H & Yaegashi N 2008 Loss of estrogen receptor b isoform expression and its correlation with aberrant DNA methylation of the 5'-untranslated region in human epithelial ovarian carcinoma. Cancer Science 99 2365-2372. (doi:10.1111/j.1349- 7006.2008.00988.x)
135. Thelen P, Scharf JG, Burfeind P, Hemmerlein B, Wuttke W, Spengler B, Christoffel V, Ringert RH & Seidlova-Wuttke D 2005 Tectorigenin and other phytochemicals extracted from leopard lily Belamcanda chinensis affect new and established targets for therapies in prostate cancer. Carcinogenesis 26 1360-1367. (doi:10.1093/carcin/bgi092)
136. Thelen P, Peter T, Hunermund A, Kaulfuss S, Seidlova-Wuttke D,Wuttke W, Ringert RH & Seseke F 2007 Phytoestrogens from Belamcanda chinensis regulate the expression of steroid receptors and related cofactors in LNCaP prostate cancer cells. BJU International 100 199-203. (doi:10.1111/j.1464-410X.2007. 06924.x)
137. Thelen P, Wuttke W & Seidlova-Wuttke D 2014 Phytoestrogens selective for the estrogen receptor β exert anti-androgenic effects in castration resistant prostate cancer. Journal of Steroid Biochemistry and Molecular Biology 139 290-3. (doi:10.1016/j.jsbmb.2013.06.009)
138. Tilley WD, Horsfall DJ, McGee MA, Henderson DW & Marshall VR 1985 Distribution of oestrogen and androgen receptors between the stroma and epithelium of the guinea-pig prostate. Journal of Steroid Biochemistry 22 713-719. (doi:10.1016/0022-4731(85)90276-6)
139. Vadlamudi RK, Wang RA, Mazumdar A, Kim Y, Shin J, Sahin A & Kumar R 2001 Molecular cloning and characterization of PELP1, a novel human coregulator of estrogen receptor a. Journal of Biological Chemistry 276 38272-38279.
140. Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, van Rooij HC, Trapman J, Brinkmann AO & Mulder E 1990 A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochemical and Biophysical Research Communications 173 534-540. (doi:10.1016/S0006-291X(05)80067-1)
141. Vermeulen A, Kaufman JM, Goemaere S & van Pottelberg I 2002 Estradiol in elderly men. Aging Male 5 98-102.
142. Waltering KK, Urbanucci A & Visakorpi T 2012 Androgen receptor (AR) aberrations in castration-resistant prostate cancer. Molecular and Cellular Endocrinology 360 38-43. (doi:10.1016/j.mce.2011.12.019)
143. Wang Q, Li W, Liu XS, Carroll JS, Janne OA, Keeton EK, Chinnaiyan AM, Pienta KJ & Brown M 2007 A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Molecular Cell 27 380-392. (doi:10.1016/j.molcel.2007.05.041)
144. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M et al. 2009 Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138 245-256. (doi:10.1016/j.cell.2009.04.056)
145. Wang D, Garcia-Bassets I, Benner C, Li W, Su X, Zhou Y, Qiu J, Liu W, Kaikkonen MU, Ohgi KA et al. 2011 Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature 474 390-394. (doi:10.1038/nature10006)
146. Weitsman GE, Skliris G, Ung K, Peng B, Younes M, Watson PH & Murphy LC 2006 Assessment of multiple different estrogen receptor-βantibodies for their ability to immunoprecipitate under chromatin immunoprecipitation conditions. Breast Cancer Research and Treatment 100 23-31. (doi:10.1007/s10549- 006-9229-5)
147. Wernert N, Gerdes J, Loy V, Seitz G, Scherr O & Dhom G 1988 Investigations of the estrogen (ER-ICA-test) and the progesterone receptor in the prostate and prostatic carcinoma on immunohistochemical basis. Virchows Archiv. A, Pathological Anatomy and Histopathology 412 387-391. (doi:10.1007/BF00750267)
148. Wu SL, Jones E, Gulley JL, Arlen PM, Chen CC, Figg WD & Dahut WL 2007 Routine interval computed tomography to detect new soft-tissue disease might be unnecessary in patients with androgen-independent prostate cancer and metastasis only to bone. BJU International 99 525-528. (doi:10.1111/j.1464-410X. 2006.06654.x)
149. Wuttke W, Jarry H, Westphalen S, Christoffel V & Seidlova-Wuttke D 2002 Phytoestrogens for hormone replacement therapy? Journal of Steroid Biochemistry and Molecular Biology 83 133-147. (doi:10.1016/ S0960-0760(02)00259-5)
150. Yang L, Ravindranathan P, Ramanan M, Kapur P, Hammes SR, Hsieh JT & Raj GV 2012 Central role for PELP1 in nonandrogenic activation of the androgen receptor in prostate cancer. Molecular Endocrinology 26 550-561. (doi:10.1210/me.2011-1101)
151. Yao S, Till C, Kristal AR, Goodman PJ, Hsing AW, Tangen CM, Platz EA, Stanczyk FZ, Reichardt JK, Tang L et al. 2011 Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested case-control study. Cancer Causes & Control 22 1121-1131. (doi:10.1007/s10552-011-9787-7)
152. Zellweger T, Sturm S, Rey S, Zlobec I, Gsponer JR, Rentsch CA, Terracciano LM, Bachmann A, Bubendorf L & Ruiz C 2013 Estrogen receptor βexpression and androgen receptor phosphorylation correlate with a poor clinical outcome in hormone-naive prostate cancer and are elevated in castration-resistant disease. Endocrine-Related Cancer 20 403-413. (doi:10.1530/ERC-12-0402)
153. Zhao Y, Agarwal VR, Mendelson CR & Simpson ER 1997 Transcriptional regulation of CYP19 gene (aromatase) expression in adipose stromal cells in primary culture. Journal of Steroid Biochemistry and Molecular Biology 61 203-210. (doi:10.1016/S0960-0760(97)80013-1)
154. Zhao C, Lam EW, Sunters A, Enmark E, De Bella MT, Coombes RC, Gustafsson JA & Dahlman-Wright K 2003 Expression of estrogen receptor β isoforms in normal breast epithelial cells and breast cancer: regulation by methylation. Oncogene 22 7600-7606. (doi:10.1038/sj.onc.1207100)
155. Zhao C, Matthews J, Tujague M, Wan J, Strom A, Toresson G, Lam EW, Cheng G, Gustafsson JA & Dahlman-Wright K 2007 Estrogen receptor β2 negatively regulates the transactivation of estrogen receptor a in human breast cancer cells. Cancer Research 67 3955-3962. (doi:10.1158/ 0008-5472.CAN-06-3505)
156. Zhao C, Gao H, Liu Y, Papoutsi Z, Jaffrey S, Gustafsson JA & Dahlman-Wright K 2010 Genome-wide mapping of estrogen receptor-β- bindingregions reveals extensive cross-talk with transcription factor activator protein-1. Cancer Research 70 5174-5183. (doi:10.1158/0008-5472.CAN-09-4407)
157. Zhu X, Leav I, Leung YK, Wu M, Liu Q, Gao Y, McNeal JE & Ho SM 2004 Dynamic regulation of estrogen receptor-β expression by DNA methylation during prostate cancer development and metastasis. American Journal of Pathology 164 2003-2012. (doi:10.1016/S0002-9440(10)63760-1)